© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lung Cancer
FDA Approves Frontline Nivolumab/Ipilimumab for Malignant Pleural Mesothelioma
October 02, 2020
The FDA approved nivolumab in combination with ipilimumab for the frontline treatment of adult patients with unresectable malignant pleural mesothelioma.
Longer Survival Observed With Atezolizumab for High PD-L1 NSCLC
October 01, 2020
In a phase 3 trial, atezolizumab demonstrated a significantly longer overall survival in patients with non-small cell lung cancer who had high PD-L1 expression regardless of histologic type compared with platinum-based chemotherapy.
Afatinib Induces Responses in Rare EGFR-Mutant Non-Small Cell Lung Cancers
October 01, 2020
Afatinib monotherapy demonstrated clinical activity in Asian and non-Asian patients with non–small cell lung cancer who harbored uncommon EGFR mutations, according to findings from a subanalysis of the afatinib uncommon mutation database.
Genomic Testing Is Necessary in Non-Small Cell Lung Cancer
September 29, 2020
Vivek Subbiah, MD, shares his take home message regarding the treatment of patients with non–small cell lung cancer who harbor a RET fusion.
Thyroid Toxicity May Predict Response to Immunotherapy in Metastatic NSCLC
September 22, 2020
The presence of hypothyroidism caused by treatment with immunotherapy correlated with improvement in overall survival among patients with non–small cell lung cancer, suggesting that thyroid toxicity may be a predictor of response to immunotherapy in this patient population.
Survival Improvement Observed with Cemiplimab in Frontline Advanced PD-L1+ NSCLC
September 21, 2020
In the phase 3 EMPOWER-Lung 1 trial, patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells, had a significant improvement in overall survival and progression-free survival with cemiplimab-rwlc monotherapy compared with platinum-doublet chemotherapy.
Phase 3 Trial Results Do Not Support PORT in Resected Stage IIIAN2 NSCLC
September 20, 2020
Patients with completely resected stage IIIAN2 non–small cell lung cancer should not be recommended for post-operative radiotherapy, according to results from the phase 3 LungART trial that were presented during the ESMO Virtual Congress 2020, due to nonstatistically significant increase in disease-free survival versus those treated in the control group.
Frontline Lorlatinib Leads to Better Outcomes Compared With Crizotinib in Advanced ALK+ NSCLC
September 20, 2020
According to results from the phase 3 CROWN trial, the third-generation ALK tyrosine kinase inhibitor loralitinib achieved a significant improvement in progression-free survival as well as higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.
Despite High Post-Surgical Mortality, Promising Responses Observed With Neoadjuvant Durvalumab in NSCLC
September 19, 2020
The use of durvalumab as treatment of patients with resectable non–small cell lung cancer in the neoadjuvant setting showed preliminary promise with a satisfactory complete surgical resection rate, according to the phase 2 IFCT-1601 IONESC study.
Tumor Regression Is Observed With Neoadjuvant Atezolizumab in Resectable NSCLC
September 19, 2020
In patients with non–small cell lung cancer who were eligible for surgical resection, treatment with one dose of neoadjuvant atezolizumab was considered safe and induced major pathological responses in some patients.